Stock Events

Regencell Bioscience 

$6.69
3
-$0.52-7.16% Friday 20:00

Statistics

Day High
6.95
Day Low
6.6
52W High
32.44
52W Low
3.03
Volume
8,505
Avg. Volume
193,559
Mkt Cap
94.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Feb 18
$0.22
Dec 17
$0.22
Sep 17
$0.22
Jun 17
$0.22
Mar 17
$0.22
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

31OctExpected
Q2 2020
Q3 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-33.38
-22.25
-11.13
0
Expected EPS
0
Actual EPS
-0.3

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGC. It's not an investment recommendation.
Alphabet
72554
GOOGL
Apple
63389
AAPL
Microsoft
59081
MSFT
Amazon
54705
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that overlaps with Regencell's focus on regenerative medicine, making them direct competitors in the biotech innovation space.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the genome editing field, directly competing with Regencell in the development of treatments for genetic diseases and conditions.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is a leading developer of CRISPR/Cas9 gene-editing therapies, competing with Regencell in the race to develop genetic treatments.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio focuses on gene therapies for severe genetic diseases and cancer, areas that overlap with Regencell's therapeutic interests.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with Regencell in the development of novel genetic treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Regencell in the broader biotech market.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other serious diseases, competing with Regencell in the market for innovative therapeutic solutions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Regencell in the field of genetic medicine.
Beam Therapeutics
BEAM
Mkt Cap2.2B
Beam Therapeutics focuses on precision genetic medicines using base editing, a form of gene editing, placing it in direct competition with Regencell's gene-based therapies.
Pfizer
PFE
Mkt Cap164.39B
Pfizer, a large pharmaceutical company, has been expanding its investment in biotechnology and gene therapy, making it a competitor to Regencell in the broader market for innovative treatments.

About

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Show more...
CEO
Employees
12
Country
KY
ISIN
KYG7487R1002

Listings

XNAS
US
RGC